DNMT3A Gene Modifications
- Detailed Technology Description
- Immune Cells with DNMT3A Gene Modifications (SJ-16-0009)Chemotherapy is the standard of care for the treatment of many types of cancer, but alternative methods are needed when chemotherapy is not ef
- *Abstract
-
Immune Cells with DNMT3A Gene Modifications (SJ-16-0009)Chemotherapy is the standard of care for the treatment of many types of cancer, but alternative methods are needed when chemotherapy is not effective. T cell therapy is one increasingly effective alternative treatment, which uses the human immune system to attack cancerous cells by finding specific proteins expressed on certain cancerous hematological cells. For example, T cells altered to bind CD19 can induce remissions of cancer with chemotherapy-refractory acute lymphoblastic leukemia. Researchers at St. Jude discovered the DNMT3A gene in immune cells may be used in adoptive T cell therapies to enhance immune responses against cancer or chronic infections by deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells. Modified DNMT3A cells can be engineered to express a chimeric antigen receptor (CAR) specific to a cancer or chronic pathogen, and transferred to a patient for treatment in combination with immune checkpoint blockade therapies. In addition to T cells, this could be used in other immune cells with various antibodies to overcome cancer, or chronic viral and/or bacterial infection.
- Country/Region
- USA
For more information, please click Here
